Teva to Present at the Cowen and Company 31st Annual Health Care Conference

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the Cowen and Company 31st Annual Health Care Conference with William Marth, President & CEO, Teva Pharmaceuticals – Americas, presenting on Monday, March 7, 2011 in Boston.

What:

  Teva Presentation at the Cowen and Company 31st Annual Health Care Conference
 

Who:

William Marth, President & CEO, Teva Pharmaceuticals – Americas
 

When:

Monday, March 7, 2011 at 10:35am EST

 

Where:

www.tevapharm.com/financial/ or

http://www.wsw.com/webcast/cowen3/teva/

 

How:

Live over the Internet – log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on Teva's website.

 

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.



CONTACT:

IR:
Teva Pharmaceutical Industries Ltd.
Elana Holzman, 972 (3) 926-7554
or
Teva North America
Kevin C. Mannix, 215-591-8912
or
PR:
Teva Pharmaceutical Industries Ltd.
Yossi Koren, 972 (3) 926-7687
or
Teva North America
Denise Bradley, 215-591-8974

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  General Health

MEDIA:

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.